Edition:
United States

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

14.00USD
18 Aug 2017
Change (% chg)

$-0.35 (-2.44%)
Prev Close
$14.35
Open
$14.26
Day's High
$14.29
Day's Low
$13.90
Volume
198,305
Avg. Vol
239,672
52-wk High
$19.50
52-wk Low
$13.45

LXRX.OQ

Chart for LXRX.OQ

About

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of... (more)

Overall

Beta: 0.33
Market Cap(Mil.): $1,478.14
Shares Outstanding(Mil.): 105.58
Dividend: --
Yield (%): --

Financials

  LXRX.OQ Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -1.33 -- --
ROI: -42.10 2.83 14.89
ROE: -85.52 5.09 16.13

BRIEF-Lexicon Pharmaceuticals reports data from pivotal phase 3 intandem2 study of sotagliflozin

* Lexicon Pharmaceuticals reports additional positive data from pivotal phase 3 intandem2 study of sotagliflozin

Aug 15 2017

BRIEF-Lexicon Pharmaceuticals reports opt-in decision for U.S. co-promotion of sotagliflozin with Sanofi in type 1 diabetes

* Lexicon Pharmaceuticals announces opt-in decision for u.s. Co-Promotion of sotagliflozin with Sanofi in type 1 diabetes

Jul 31 2017

BRIEF-Lexicon collaborator Ipsen receives positive CHMP opinion for Xermelo

* Lexicon collaborator Ipsen receives positive CHMP opinion for Xermelo® (telotristat ethyl) Source text for Eikon: Further company coverage:

Jul 21 2017

BRIEF-Lexicon Pharmaceuticals amends collaboration and license agreement

* Lexicon Pharmaceuticals - on july 1, 2017, entered into an amendment to collaboration and license agreement with Sanofi-Aventis Deutschland GMBH

Jul 07 2017

BRIEF-Lexicon Pharmaceuticals says Xermelo 250 mg has been included as a recommended treatment option in latest national comprehensive cancer network

* Lexicon Pharmaceuticals Inc - Xermelo 250 mg has been included as a recommended treatment option in latest national comprehensive cancer network

Jun 19 2017

BRIEF-Lexicon Pharmac reports positive late-stage data on diabetes drug

* Lexicon Pharmaceuticals reports positive top-line results in phase 3 intandem3 study for sotagliflozin in patients with type 1 diabetes

Jun 09 2017

BRIEF-Lexicon Pharmaceuticals reports Q1 revenue $18.3 million

* Lexicon Pharmaceuticals reports first quarter 2017 financial results and provides a business update

May 02 2017

BRIEF-Lexicon Pharmaceuticals enters into sixth amendment to loan and security agreement

* Lexicon Pharmaceuticals-on April 20, units entered into sixth amendment to loan and security agreement and to other loan documents with istar lex lender

Apr 21 2017

BRIEF-Lexicon Pharma files for offering of up to $10.1 mln by selling stockholders - SEC filing

* Files for secondary offering of up to $10.1 million by selling stockholders - SEC filing Source text - http://bit.ly/2nD7v4q Further company coverage:

Mar 20 2017

BRIEF-Lexicon Pharmaceuticals reports Q4 loss per share $0.31

* Lexicon Pharmaceuticals provides clinical pipeline update and reports 2016 fourth quarter and full year financial results

Mar 03 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $32.67 -0.28
Roche Holding Ltd. (ROG.S) CHF241.40 -2.80
Roche Holding Ltd. (RO.S) CHF244.50 -2.30
Merck & Co., Inc. (MRK.N) $61.49 -0.32
Bayer AG (BAYGn.DE) €107.90 -0.20
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €82.26 -0.50
Eli Lilly and Co (LLY.N) $77.07 -0.73
Abbott Laboratories (ABT.N) $48.74 -0.55
Bristol-Myers Squibb Co (BMY.N) $56.42 -0.35

Earnings vs. Estimates